BioCentury | Nov 19, 2019
Company News

Nov. 19 Company Quick Takes: Medicines Co. gains on buyout rumor; plus Samsung's biosimilar under review and Zelluna-Glycostem

Medicines Co. mum on Novartis takeout rumor The Medicines Co. (NASDAQ:MDCO) declined to comment to BioCentury on a Bloomberg report that said Novartis AG (NYSE:NVS; SIX:NOVN) is among several companies exploring an acquisition of the...
BioCentury | Mar 15, 2018
Product R&D

Engineered to kill

Nkarta Inc. is betting that boosting NK cells’ intrinsic ability to discriminate between cancer and healthy cells will increase their efficacy as anti-cancer agents and lower their risk of toxicity compared with the more common...
BioCentury | Feb 16, 2018
Product R&D

Banking on the placenta

Celgene Corp. spinout Celularity Inc. is aiming to disrupt the stem cell market with a platform of placenta-based cell therapies whose intrinsic allo-tolerance could provide a broadly applicable system for propelling off-the-shelf cancer therapies into...
BioCentury | Aug 31, 2017
Translation in Brief

Fate’s killer memory

Fate Therapeutics Inc. has published the cell culture methodology behind Fate-NK100 , its adoptive memory NK cell therapy in Phase I testing for cancer, and created two off-the-shelf versions of the candidate using iPS cells. According...
BioCentury | Jan 26, 2017
Translation in Brief

NK cell double take

NK cells are raising interest in immuno-oncology with potential safety benefits and broader activity than their T cell counterparts, but achieving sufficiently high levels of activation is an ongoing challenge. Affimed N.V. (NASDAQ: AFMD) thinks...
BioCentury | Jul 28, 2016
Tools & Techniques

Innate harmony

On the heels of cancer immunotherapy's clinical success, NK cells - a long-known but underappreciated component of the innate immune system - are emerging as the hottest new tool to fight cancer, with the potential to be...
BioCentury | Mar 15, 2010
Company News

Biocompatibles, Celsion, Cortius B.V., Glycostem Therapeutics, ISA Pharmaceuticals, IQ Corp. B.V., Percuros B.V., Biomedical Materials, Center for Translational

The Biomedical Materials program, the Center for Translational Molecular Medicine and Top Institute Pharma, all public-private partnerships, jointly awarded €28 million ($38.2 million) to seven research programs, including three projects for cancer, three for drug...
Items per page:
1 - 7 of 7
BioCentury | Nov 19, 2019
Company News

Nov. 19 Company Quick Takes: Medicines Co. gains on buyout rumor; plus Samsung's biosimilar under review and Zelluna-Glycostem

Medicines Co. mum on Novartis takeout rumor The Medicines Co. (NASDAQ:MDCO) declined to comment to BioCentury on a Bloomberg report that said Novartis AG (NYSE:NVS; SIX:NOVN) is among several companies exploring an acquisition of the...
BioCentury | Mar 15, 2018
Product R&D

Engineered to kill

Nkarta Inc. is betting that boosting NK cells’ intrinsic ability to discriminate between cancer and healthy cells will increase their efficacy as anti-cancer agents and lower their risk of toxicity compared with the more common...
BioCentury | Feb 16, 2018
Product R&D

Banking on the placenta

Celgene Corp. spinout Celularity Inc. is aiming to disrupt the stem cell market with a platform of placenta-based cell therapies whose intrinsic allo-tolerance could provide a broadly applicable system for propelling off-the-shelf cancer therapies into...
BioCentury | Aug 31, 2017
Translation in Brief

Fate’s killer memory

Fate Therapeutics Inc. has published the cell culture methodology behind Fate-NK100 , its adoptive memory NK cell therapy in Phase I testing for cancer, and created two off-the-shelf versions of the candidate using iPS cells. According...
BioCentury | Jan 26, 2017
Translation in Brief

NK cell double take

NK cells are raising interest in immuno-oncology with potential safety benefits and broader activity than their T cell counterparts, but achieving sufficiently high levels of activation is an ongoing challenge. Affimed N.V. (NASDAQ: AFMD) thinks...
BioCentury | Jul 28, 2016
Tools & Techniques

Innate harmony

On the heels of cancer immunotherapy's clinical success, NK cells - a long-known but underappreciated component of the innate immune system - are emerging as the hottest new tool to fight cancer, with the potential to be...
BioCentury | Mar 15, 2010
Company News

Biocompatibles, Celsion, Cortius B.V., Glycostem Therapeutics, ISA Pharmaceuticals, IQ Corp. B.V., Percuros B.V., Biomedical Materials, Center for Translational

The Biomedical Materials program, the Center for Translational Molecular Medicine and Top Institute Pharma, all public-private partnerships, jointly awarded €28 million ($38.2 million) to seven research programs, including three projects for cancer, three for drug...
Items per page:
1 - 7 of 7